Abstract
A recent review showed frequent reductions of sorafenib dose in the treatment of metastatic thyroid cancer because of toxicity consistent with the findings of the phase III DECISION trial and contrasting with the safety of sorafenib in other cancer populations. The unexpected excess of toxicity observed in thyroid cancer patients may be linked to a high prevalence of sarcopenia in this population, resulting in frequent overexposure to sorafenib.